Mexican Delphi Consensus for use Immunotherapy with MV130 Vaccine in Patients with Recurrent Respiratory Infectious Diseases (Expert Panel)

Abstract

Background and Objectives: Recurrent respiratory infections are currently a public health problem due to their high costs and resistance to treatments as well increase morbidity and mortality. An imbalance in the homeostasis of progressive cellular and humoral immunity the application of immunotherapy with trained immunity vaccines (IvIE) is currently a therapeutic option in all patients with recurrent respiratory infections by training innate and adaptive immunity by reducing episodes of respiratory exacerbations and improving the quality of life of patients.

Methods: Using Delphi method and a panel of experts, a questionnaire was developed that included questions regarding the benefit and non-benefit of the treatment of patients with persistence of recurrent respiratory infections by specific criteria, from diagnosis, identification of risk factors and comorbidities, ideal candidate by consensus to receive the therapy, follow-up, and presentation of clinical data for reduction of recurrence of the conditions. There was a consensus on determining the use of immunotherapy MV130 vaccine in patients with specific criteria as long- and short-term use.

Conclusion: Immunotherapy with trained immunity vaccines (IvIE) is currently a therapeutic option in all patients with recurrent respiratory infections and associated comorbidities in patients with chronic respiratory illnesses, autoimmune diseases, hematological malignancies for improvement clinical infections and improvement quality of life.